-
-
-
-
-
-
-
Barclays Upgrades uniQure BV (QURE) to Overweight Following 78% Gain Yesterday
-
-
-
-
-
-
-
Barclays Comments on uniQure BV (QURE) Amid 66% Gain: 'a major positive'
-
-
-
-
-
-
-
Mizuho Upgrades uniQure BV (QURE) to Outperform, Raise PT to $35
-
-
-
-
-
-
-
TD Cowen Reiterates Buy Rating on uniQure BV (QURE)
-
-
-
-
-
-
-
Stifel Reiterates Buy Rating on uniQure BV (QURE)
-
-
-
-
-
-
-
uniQure reports sustained enzyme activity in Fabry disease gene therapy trial
-
-
-
-
-
-
-
uniQure receives FDA feedback on Huntington's disease gene therapy
-
459,814 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

